By chance, Mizushima Yuu brought this patent for the benefit of mankind to the people of China.
14 years ago, Professor Mizushima Yuu, then director of the Center for Treatment and Research of Difficult Diseases of Santa Mariana Medical University, visited China for the first time. He was invited to China by Beijing Sino-Japanese Friendship Hospital. After the academic exchange, colleagues from the hospital accompanied him to the long-awaited Great Wall. Standing on the height of the Great Wall and overlooking the mountains, Mizushima Yuu is filled with emotion and has deep feelings for this beautiful and enthusiastic country.
When he returned to Japan, the president of China-Japan Friendship Hospital personally went to the airport to deliver water to Yudao. From the words in the lunch room, Mizushima Yuu learned that the China-Japan Friendship Hospital has been established for nearly 10 years, and the Japanese government's free assistance will stop at 1994. In this way, it is difficult to update the hospital's equipment and scientific research funds. When Mizushima Yuu heard the news, he immediately told the dean that he would donate one of his best patents and use the profits to develop the hospital.
The donation process went smoothly unexpectedly, but the drug production was stumped by another thing.
Beijing Taide Pharmaceutical Co., Ltd., which came into being to produce this drug, has been unable to put into normal production due to the shortage of funds. After learning this news, Mizushima Yuu ran around and finally made an amazing move: taking personal property as collateral and borrowing money from the bank! In this way, he borrowed more than 654.38 billion yen from the bank and purchased the main production equipment, and the whole drug production was put on the agenda. And this loan of 1 100 million yen, Mizushima Yuu refused to share with others in the next five years, and repaid it alone in batches.
Where there is a will, there is a way. 1998, China's first "drug missile" product named "Shikai" was officially launched. In recent years, Shikai has sold 654.38+0.5 billion yuan in China, benefiting more than 654.38+0.00 million patients. The successful introduction of this technology has filled a gap in the field of related drugs in China, and also made China reach the world advanced level in the field of nano-pharmaceutical technology and "drug missiles".
In 2000, another patent of Mizushima Yuu was introduced into Beijing Taide Pharmaceutical Co., Ltd.; In 2004, a new targeted analgesic drug "Kaifen" produced according to this patent was officially listed, and the market prospect was bright.
In 2007, Mizushima Yuu negotiated with China and provided Beijing Taide Pharmaceutical Co., Ltd. with his third patent for biological agents used to treat refractory diseases. ..
In the past two years, the Japan-China Center for Exchange of Traditional Chinese Medicine, chaired by Mizushima Yuu, has also cooperated with Japan's Matian General Hospital to establish a Japan-China Friendship Hospital in Tokyo, Japan. From June 5438 to October 30, 2007, the hospital was officially opened, providing Chinese medical services six days a week for China people who can't speak Japanese, and also providing Japanese medical services for Japanese patients who trust Chinese medicine. The newly opened hospital became his window to provide medical services for Chinese people in Japan.
He died in Tokyo at 8 am on May 7, 2008 at the age of 74.